Open Beta
TREN
MetriLume
TREN

US marketsALGS

SEC-sourced researchBeta

ALGS

Aligos Therapeutics, Inc.

Company comparison ↗

Data passport

CIK
0001799448
Exchange
Nasdaq
Business activity
Biological Products, (No Diagnostic Substances) · SIC 2836
Financial inputs
6/6
Filing date
Sep 15, 2026
SEC registry record
Operating company
Last updated: SEC company ticker catalog ↗SEC Financial Statement Data Sets ↗SEC investment company series and class registry ↗

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table. Exact amounts and source periods: December 2024: 3,611,000.0000 USD; December 2025: 2,186,000.0000 USD3.6M USD0 USD0December 2024December 2025
ALGS · Exact amounts and source periods · USD
Period endRevenueFiling date
December 20243,611,000.0000Mar 5, 2026
December 20252,186,000.0000Mar 5, 2026

Annual periods · USD

Period endRevenueNet incomeOperating cash flowTotal assetsTotal liabilitiesFiling date
December 20252,186,000.0000-24,193,000.0000-82,503,000.000088,533,000.000034,988,000.0000Mar 5, 2026
December 20243,611,000.0000-131,211,000.0000-80,743,000.000070,094,000.000099,067,000.0000Mar 5, 2026

Explainable fundamental score

Five equally weighted components based on SEC financial inputs. No price inputs or personal investment preferences.

34/100
Profitability0
Growth11
Balance sheet60
Cash generation0
Data coverage100

Component weight: 20% · Minimum data coverage: 50% · Missing component value: 50/100

Financial inputs behind the calculation

Financial inputsUSDPeriod endFiling dateForm
RevenueRevenueFromContractWithCustomerExcludingAssessedTax$2.19MJan 1, 2025 – Dec 31, 2025Mar 5, 202610-K
Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax$3.61MJan 1, 2024 – Dec 31, 2024Mar 5, 202610-K
Net incomeNetIncomeLoss-$24.19MJan 1, 2025 – Dec 31, 2025Mar 5, 202610-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities-$82.5MJan 1, 2025 – Dec 31, 2025Mar 5, 202610-K
Total assetsAssets$88.53MDec 31, 2025Mar 5, 202610-K
Total liabilitiesLiabilities$34.99MDec 31, 2025Mar 5, 202610-K

New filings

Explore methodology ↗